Business Wire

HYTERA-COMMUNICATIONS

25.5.2023 17:30:27 CEST | Business Wire | Press release

Share
Hytera Mission-critical Push-to-talk Solution Wins Flagship Industry Award

Hytera Communications (SZSE: 002583), a leading global provider of professional communications technologies and solutions, received the award of “Best use of critical communications in utilities” with its entry “LECO Electricity MCPTT” at the International Critical Communications Awards (ICCAs) 2023 ceremony held in Helsinki, Finland on May 23. The ICCAs, presented by the Critical Communications Association (TCCA), is a highly-anticipated program recognizing the success of products, organizations, and individuals that have pushed boundaries and capabilities within the field of critical communications. Earlier in April, Hytera’s seven entries were shortlisted by ICCAs.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230525005622/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Tony Gray, former CEO of TCCA, presenting the ICCA award to Hytera representative (on the right) (Photo: Business Wire)

This Mission-critical Push-to-talk (MCPTT) deployment highlights a clear path for the migration of the private communications network in the utility sector. Working with local partner Dialog Enterprise, Hytera has deployed a customized MCPTT system for LECO, Lanka Electricity Company (Private) Limited. As the rapid-response arm of the Ceylon Electricity Board, LECO provides electrical services to underserved areas and now works with a state-of-the-art radio communications system based on MCPTT over 4G-LTE technology to cover service grids in Galle, Moratuwa, Kalutara, Negombo, Kelaniya, Kotte, and Nugegoda. In the extreme scenario where cellular network coverage is not available, Hytera’s dual-mode rugged radios support device-to-device (D2D) communication empowered by Digital Mobile Radio (DMR) technology. While it proves the versatility of MCPTT to serve utility companies, the project also demonstrates how product innovations, such as dual-mode radios, can win the users’ buy-ins in technology adoption.

“This MCPTT solution operates at a higher priority than Internet services, and also having a device-to-device communication mode are huge pluses for LECO,” said Athula P. De Silva, Chairman of LECO. “Because when connectivity is interrupted due to unforeseeable circumstances–like a sudden violent storm, for instance–we are the professionals whose job it is to bring the network back up. With this, our dispatchers and field engineers are in constant touch since we are in complete control of our own internal communication channel. So, in the event of an outage, power can be restored much faster. If we had chosen the generic mobile voice service or Push-to-talk over Cellular (PoC) instead, our rapid response team’s communications would have been vulnerable to the same disruptive factors and service interruptions as the general public–and that was totally unacceptable. We are the first line of defense against power outages. MCPTT solution is a perfect fit for our requirements.”

Hytera HyTalk MC Mission Critical Services (MCS) system is a multimedia mission-critical communication solution designed for sectors such as public safety, utilities, and transportation. It is fully compliant with the 3GPP MC standards including MCPTT, MCData, and MCVideo. It delivers reliable voice and video communication, high-speed data transfer, and multimedia dispatch services for daily operations. It helps enhance connectivity for better collaboration and improved situational awareness.

Priority Quality of Service (QoS) of HyTalk MC is guaranteed on the servers of the MCPTT platform provider and on the mobile operator's network. This end-to-end QoS ensures that critical communications users are given the highest priority available over any other commercial users. HyTalk MC also enables Professional Mobile Radio (PMR) to LTE interoperability, so that it allows connections among different task forces.

“The award is a great recognition to all the stakeholders of this project, including LECO and Dialog. This case epitomizes how technological advancements are introduced and adopted to empower professionals from the utility sector,” said Ming Kam Wong, deputy GM of Hytera overseas business, who was present at the ICCAs ceremony. “Hytera is humbled to see itself becoming a frequent participant and winner of ICCAs. Thank you to the panel and congratulations to all the winners of ICCAs 2023.”

About Hytera

Hytera Communications Corporation Limited (SZSE: 002583) is a leading global provider of professional communications technologies and solutions. With voice, video and data capabilities, we provide faster, safer, and more versatile connectivity for business and mission critical users. We make the world more efficient and safer by enabling our customers to achieve more in both daily operations and emergency response. Learn more at https://www.hytera.com/en/home.html.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230525005622/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye